secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-04-13T23:59:59+00:00
Accession:  0001193125-26-152826
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma stockholders approve reverse stock split with ratio 1:30 to 1:50
------------------------------------------------------------------------------

- Elected Pasha Sarraf, Peter A. Kiener, Frank Morich, Pamela Garzone, Patrick Verheyen, and Jill Broadfoot to the Board.
- Ratified RSM US LLP as independent auditor for FY2026 with 58,982,168 votes for.
- Approved non-binding advisory say-on-pay with 31,388,709 for, 4,239,819 against.
- Approved reverse stock split amendment at 51,011,729 for; ratio range 1-for-30 to 1-for-50 at Board's discretion.
- Prior CEO Usman Azam resigned March 26, 2026; votes for him were disregarded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526152826/0001193125-26-152826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526152826/cue-20260413.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-152826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer